Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats
Source: SeekingAlpha
2025-11-05 12:38:45 ET
More on Rigel Pharmaceuticals
- Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
- Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
- Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
- Rigel raises 2025 revenue guidance to $285M–$290M as commercial sales growth accelerates
- Rigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
-3.13% G/L:
$26.0825 Last:
96,605 Volume:
$26.87 Open:
RIGL Latest News
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
